Locally Advanced Breast Cancer Clinical Trial
Official title:
Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemotherapy Among Locally Advanced Breast Cancer Patients: a Single-center, Prospective, Exploratory Clinical Trial
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. The purpose of this clinical trial is to evaluate the predictive value of CTC in neoadjuvant chemotherapy among locally advanced breast cancer patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01048918 -
Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer
|
||
| Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05744375 -
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
|
Phase 2 | |
| Terminated |
NCT01837563 -
Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer
|
N/A | |
| Recruiting |
NCT03978663 -
Three Fraction Radiation to Induce Immuno-Oncologic Response
|
N/A | |
| Active, not recruiting |
NCT04352777 -
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT06064812 -
A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.
|
Phase 1 | |
| Recruiting |
NCT05963997 -
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06080620 -
The Choice of Treatment Methods and Efficacy of LABC
|
N/A | |
| Completed |
NCT05002868 -
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02595762 -
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
|
||
| Active, not recruiting |
NCT02965950 -
The p53 Breast Cancer Trial
|
Phase 2 | |
| Completed |
NCT01785992 -
A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.
|
Phase 2 | |
| Completed |
NCT00764036 -
Study of Artesunate in Metastatic Breast Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03685331 -
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
|
Phase 1 | |
| Completed |
NCT05021900 -
Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
| Withdrawn |
NCT04088032 -
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
|
Early Phase 1 | |
| Completed |
NCT00455273 -
Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer
|
||
| Terminated |
NCT04042051 -
Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT05582499 -
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
|
Phase 1/Phase 2 |